The EPNextS Group is dedicated to advancing global pharmaceutical development through the transformation of international collaborative clinical trials. As a total solution provider in drug development, we support the expansion of innovative therapies from Japan to the world and facilitate the entry of pharmaceutical companies worldwide into Japan and Asia.
We work with nearly all major global pharmaceutical companies, as well as biotech innovators utilizing cutting-edge technologies. Through strong alliances with international CROs and SMOs, we continue to accelerate clinical trials and enable more efficient pharmaceutical development worldwide.
In Japan, “drug loss” has become a growing concern—situations where innovative therapies already approved overseas are not available domestically because development has not progressed. To solve this issue, the EPNextS Group focuses on both clinical and market challenges and promotes collaborative initiatives with leading global partners.
Our mission is clear: expand access to worldwide medical innovations and ensure that more patients benefit from new treatments.
For overseas companies conducting drug development in Japan, the EPS Group offers seamless, end-to-end support—from clinical development planning and regulatory affairs to site management and post-marketing operations.
Leveraging advanced digital transformation (DX) and AI-driven analytics, we optimize clinical trial processes and maximize operational efficiency. This integrated approach enables global clients to achieve their development goals smoothly and efficiently.
As international collaborative trials continue to grow, highly skilled professionals who understand diverse regulations and medical systems are essential. EPNextS provides global-standard training programs including:
These initiatives reinforce real-world practical skills and foster specialists capable of managing global-scale clinical trials.
Percentage of International Projects
April 2020 – March 2025
EPS Corp.
EP-Link
EP-PharmaLine
If you have any comments, questions, or requests for documents regarding our company or our group companies,
please use the contact form below.
